Figure 4
From: Signal transduction inhibitors in treatment of myelodysplastic syndromes
TGF-β signaling pathway. TGF-β receptors after binding with the TGF-β ligand, forms a receptor- ligand complex. This dimerization activates the kinase domain of Type I receptor. The activated Type 1 receptor kinase further activates the downstream smad complexes to regulate gene transcription. LY2157299 inhibits the TGF-β receptor I kinase and can reverse the cellular effects of TGF- β signaling pathway in hematopoietic cells.